PDSB Stock Forecast & Price Target

PDS Biotechnology is viewed positively because its lead asset PDS0301 has shown unusually strong activity in a difficult MSS/pMMR liver-metastatic mCRC setting, including 71% versus 35% 6-month ORR across sequential NCI cohorts and a published median OS not reached versus 17.9 months with HR 0.30. The planned Phase 3 submission in 4Q for a 1Q27 start, combined with FDA feedback, a manageable combination design, and a sub-200-patient study estimate at high power, supports a credible path to registrational development. Financially, the up to $22.55M PIPE, $5.6M cash at the end of 2Q26, a de-levered balance sheet, and lower operating costs after a ~36% workforce reduction improve runway while still leaving the company focused on a potentially broader oncology platform.

PDS Biotechnology is facing a fundamentally fragile investment case because its lead liver-met data come from a small, nonrandomized 22-patient study versus a 20-patient sequential comparator, making the observed 6-month ORR and survival signal difficult to rely on before mature survival data are available. Regulatory and execution risk are also elevated since the Ph3 design has not yet been accepted by FDA, approval or reimbursement is uncertain, and the regimen depends on specialized hepatic artery pump placement, enrollment pace, and toxicity management that may not match the NCI experience. Most importantly, financing risk appears dominant: the company cannot fund the Ph3 from cash in hand, depends on equity raises beyond the committed $11M milestone closing, and management has indicated about $15M is needed for the randomized mCRC study and another $15M for operations, leaving dilution and going-concern risk central.